Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open Label, Phase II Clinical Trial Evaluating the Combination of Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

NCT07901868 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07901868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open Label, Phase II Clinical Trial Evaluating the Combination of Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2032
Enrollment
60 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, multiple myeloma refractory

Arms

As registered; 2 arms.

  • Negative minimal residual disease at end cycle 12 Active comparatorDexamethasone, Elranatamab, Mezigdomide

    All participants will receive Elranatamab, Mezigdominde and Dexametahsone in 28-day cycles as follows:

    * Oral Mezigdomide: dose of 0.6 mg daily on days 1 to 21 of each cycle (from cycle 2 onwards).
    * Oral Dexamethasone: dose of 20 mg/day (≤ 75 years old) or 10 mg/day (\>75 years old) from cycle 1 to 6.
    * Subcutaneous Elranatamab:

    Cycle 1: day1 (step-up dose 12 mg), day4 (step-up dose 32 mg), day8 (target dose 76 mg), day15 (76 mg), and day22 (76 mg).

    Cycles 2 and 3: day1 and day15 (76 mg) of each 28-day cycle. From cycle 4 onwards: day1 (76 mg). From Cycle 13 onwards, participants will discontinue elranatamab and will continue with mezigdomide alone.

    In those patients who discontinue elranatamab due to sustained MRD negativity, Elranatamab will be reintroduced as from the cycle 2 in case of biological progression (IMWG criteria) or positivization of MRD.

  • Positive minimal residual disease et end cycle 12 Active comparatorDexamethasone, Elranatamab, Mezigdomide

    All participants will receive Elranatamab, Mezigdominde and Dexametahsone in 28-day cycles as follows:

    * Oral Mezigdomide: dose of 0.6 mg daily on days 1 to 21 of each cycle (from cycle 2 onwards).
    * Oral Dexamethasone: dose of 20 mg/day (≤ 75 years old) or 10 mg/day (\>75 years old) from cycle 1 to 6.
    * Subcutaneous Elranatamab will be given as follows:
    * Cycle 1: day1 (step-up dose 12 mg), day4 (step-up dose 32 mg), day8 (target dose 76 mg), day15 (76 mg), and day22 (76 mg).
    * Cycles 2 and 3: day1 and day15 (76 mg) of each 28-day cycle.
    * From cycle 4 onwards: day1 (76 mg).
    * From Cycle 13 onwards, patients with positive minimal residual disease will keep receiving Elranatamab as from cycle 4 plus Mezigdomide with above indicated dose.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Proportion of patients achieving minimal residual disease (MRD) negativity. 5 years

    To evaluate the percentage of participants achieving negative MRD. Negative MRD is defined as the presence of less than 1 tumour cell among 100,000 healthy hematopoietic cells by Next Generation Flow Cytometry in bone marrow, according to the IMWG criteria.

Lead sponsor's other trials

PETHEMA Foundation, most recent start first.

Similar trials

Same condition (Neoplasm, Residual) and phase, most recent start first.